Literature DB >> 33466633

Complex Machine-Learning Algorithms and Multivariable Logistic Regression on Par in the Prediction of Insufficient Clinical Response to Methotrexate in Rheumatoid Arthritis.

Helen R Gosselt1,2, Maxime M A Verhoeven3, Maja Bulatović-Ćalasan3,4, Paco M Welsing3, Maurits C F J de Rotte5, Johanna M W Hazes6, Floris P J G Lafeber3, Mark Hoogendoorn7, Robert de Jonge1.   

Abstract

The goals of this study were to examine whether machine-learning algorithms outperform multivariable logistic regression in the prediction of insufficient response to methotrexate (MTX); secondly, to examine which features are essential for correct prediction; and finally, to investigate whether the best performing model specifically identifies insufficient responders to MTX (combination) therapy. The prediction of insufficient response (3-month Disease Activity Score 28-Erythrocyte-sedimentation rate (DAS28-ESR) > 3.2) was assessed using logistic regression, least absolute shrinkage and selection operator (LASSO), random forest, and extreme gradient boosting (XGBoost). The baseline features of 355 rheumatoid arthritis (RA) patients from the "treatment in the Rotterdam Early Arthritis CoHort" (tREACH) and the U-Act-Early trial were combined for analyses. The model performances were compared using area under the curve (AUC) of receiver operating characteristic (ROC) curves, 95% confidence intervals (95% CI), and sensitivity and specificity. Finally, the best performing model following feature selection was tested on 101 RA patients starting tocilizumab (TCZ)-monotherapy. Logistic regression (AUC = 0.77 95% CI: 0.68-0.86) performed as well as LASSO (AUC = 0.76, 95% CI: 0.67-0.85), random forest (AUC = 0.71, 95% CI: 0.61 = 0.81), and XGBoost (AUC = 0.70, 95% CI: 0.61-0.81), yet logistic regression reached the highest sensitivity (81%). The most important features were baseline DAS28 (components). For all algorithms, models with six features performed similarly to those with 16. When applied to the TCZ-monotherapy group, logistic regression's sensitivity significantly dropped from 83% to 69% (p = 0.03). In the current dataset, logistic regression performed equally well compared to machine-learning algorithms in the prediction of insufficient response to MTX. Models could be reduced to six features, which are more conducive for clinical implementation. Interestingly, the prediction model was specific to MTX (combination) therapy response.

Entities:  

Keywords:  arthritis; healthcare; methotrexate; outcome assessment; rheumatoid; therapeutics

Year:  2021        PMID: 33466633      PMCID: PMC7828730          DOI: 10.3390/jpm11010044

Source DB:  PubMed          Journal:  J Pers Med        ISSN: 2075-4426


  28 in total

1.  Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.

Authors:  Saedis Saevarsdottir; Helena Wallin; Maria Seddighzadeh; Sofia Ernestam; Pierre Geborek; Ingemar F Petersson; Johan Bratt; Ronald F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2010-12-13       Impact factor: 19.103

2.  Early Prediction of Clinical Response to Etanercept Treatment in Juvenile Idiopathic Arthritis Using Machine Learning.

Authors:  Xiaolan Mo; Xiujuan Chen; Chifong Ieong; Song Zhang; Huiyi Li; Jiali Li; Guohao Lin; Guangchao Sun; Fan He; Yanling He; Ying Xie; Ping Zeng; Yilu Chen; Huiying Liang; Huasong Zeng
Journal:  Front Pharmacol       Date:  2020-07-31       Impact factor: 5.810

3.  Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure.

Authors:  Jaap Fransen; Wouter M Kooloos; Judith A M Wessels; Tom W J Huizinga; Henk-Jan Guchelaar; Piet L C M van Riel; Pilar Barrera
Journal:  Pharmacogenomics       Date:  2012-07       Impact factor: 2.533

4.  Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate.

Authors:  M C F J de Rotte; P H P de Jong; S M F Pluijm; M Bulatović Calasan; P J Barendregt; D van Zeben; P A van der Lubbe; P B de Sonnaville; J Lindemans; J M W Hazes; R de Jonge
Journal:  Arthritis Rheum       Date:  2013-11

5.  Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.

Authors:  Johannes W J Bijlsma; Paco M J Welsing; Thasia G Woodworth; Leonie M Middelink; Attila Pethö-Schramm; Corrado Bernasconi; Michelle E A Borm; Cornelis H Wortel; Evert Jan Ter Borg; Z Nazira Jahangier; Willemijn H van der Laan; George A W Bruyn; Paul Baudoin; Siska Wijngaarden; Petra A J M Vos; Reinhard Bos; Mirian J F Starmans; Eduard N Griep; Joanna R M Griep-Wentink; Cornelia F Allaart; Anton H M Heurkens; Xavier M Teitsma; Janneke Tekstra; Anne Carien A Marijnissen; Floris P J Lafeber; Johannes W G Jacobs
Journal:  Lancet       Date:  2016-06-07       Impact factor: 79.321

6.  Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial.

Authors:  Adrian Levitsky; Kerstin Brismar; Ingiäld Hafström; Karen Hambardzumyan; Cecilia Lourdudoss; Ronald F van Vollenhoven; Saedis Saevarsdottir
Journal:  RMD Open       Date:  2017-08-09

7.  Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab.

Authors:  Inbal Haya Shafran; Farideh Alasti; Josef S Smolen; Daniel Aletaha
Journal:  Ann Rheum Dis       Date:  2020-05-05       Impact factor: 27.973

8.  Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS).

Authors:  Jamie C Sergeant; Kimme L Hyrich; James Anderson; Kamilla Kopec-Harding; Holly F Hope; Deborah P M Symmons; Anne Barton; Suzanne M M Verstappen
Journal:  Arthritis Res Ther       Date:  2018-07-13       Impact factor: 5.156

Review 9.  Applied machine learning and artificial intelligence in rheumatology.

Authors:  Maria Hügle; Patrick Omoumi; Jacob M van Laar; Joschka Boedecker; Thomas Hügle
Journal:  Rheumatol Adv Pract       Date:  2020-02-19

10.  EULAR definition of difficult-to-treat rheumatoid arthritis.

Authors:  Désirée van der Heijde; Jacob M van Laar; György Nagy; Nadia Mt Roodenrijs; Paco Mj Welsing; Melinda Kedves; Attila Hamar; Marlies C van der Goes; Alison Kent; Margot Bakkers; Etienne Blaas; Ladislav Senolt; Zoltan Szekanecz; Ernest Choy; Maxime Dougados; Johannes Wg Jacobs; Rinie Geenen; Hans Wj Bijlsma; Angela Zink; Daniel Aletaha; Leonard Schoneveld; Piet van Riel; Loriane Gutermann; Yeliz Prior; Elena Nikiphorou; Gianfranco Ferraccioli; Georg Schett; Kimme L Hyrich; Ulf Mueller-Ladner; Maya H Buch; Iain B McInnes
Journal:  Ann Rheum Dis       Date:  2020-10-01       Impact factor: 19.103

View more
  3 in total

1.  Functional coding haplotypes and machine-learning feature elimination identifies predictors of Methotrexate Response in Rheumatoid Arthritis patients.

Authors:  Ashley J W Lim; Lee Jin Lim; Brandon N S Ooi; Ee Tzun Koh; Justina Wei Lynn Tan; Samuel S Chong; Chiea Chuen Khor; Lisa Tucker-Kellogg; Khai Pang Leong; Caroline G Lee
Journal:  EBioMedicine       Date:  2022-01-10       Impact factor: 8.143

2.  Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data.

Authors:  Stephanie Q Duong; Cynthia S Crowson; Arjun Athreya; Elizabeth J Atkinson; John M Davis; Kenneth J Warrington; Eric L Matteson; Richard Weinshilboum; Liewei Wang; Elena Myasoedova
Journal:  Arthritis Res Ther       Date:  2022-07-01       Impact factor: 5.606

Review 3.  Artificial Intelligence in Rheumatoid Arthritis: Current Status and Future Perspectives: A State-of-the-Art Review.

Authors:  Sara Momtazmanesh; Ali Nowroozi; Nima Rezaei
Journal:  Rheumatol Ther       Date:  2022-07-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.